Work

Clinical and Preclinical Treatment Aspects of Castration Resistant Prostate Cancer (CRPC)

Year: 2012
Type: dissertation
Abstract: In the Western countries prostate cancer is the most frequently diagnosed cancer, except\nfor skin cancer, and the second leading cause of male cancer deaths. Prostate\ncancer tends to develop in men over the age of fifty and although it is one of the most\nprevalent types of cancer in men, many patients may never have symptoms, undergo\nno therapy, and eventually die from other causes. This is because cancer of the prostate\nis, in many cases, slow-growing, symptom-free, and since men with the condition are\nolder they often die from causes unrelated to the prostate cancer. Men diagnosed with\nclinically localized prostate cancer have several treatment options available, including\nwatchful waiting, definitive radiation therapy and surgery. However, a significant proportion\nof patients who present with cancer that appears to be localized will eventually\ndevelop incurable metastatic disease and ultimately succumb to death as a result of\nadvanced disease. In patients with advanced disease androgen-deprivation therapies\ntypically result in rapid responses, but eventually nearly all patients develop progressive\ncastration-resistant disease. Historically, clinical management for metastatic castration\nresistant prostate cancer (CRPC) has been primarily focused on relieving symptoms. In\nthe last decade the therapeutic spectrum has changed dramatically, and our understanding\nof the biology of patients with prostate cancer has become far more sophisticated.\nThe treatment paradigm first changed with the publication of 2 pivotal randomized\nclinical trials in 2004, which demonstrated for the first time a survival benefit with\ndocetaxel-based therapy in patients with metastatic CRPC. Since then, docetaxel chemotherapy\nhas become the standard first-line treatment in patients with CRPC (Chapter\n2). Recently, the landscape for CRPC treatment has changed again with the FDA approval\nof three additional therapies, sipuleucel-T5, cabazitaxel6 and abiraterone acetate7.\nWhile the addition of these new treatment options is a great advance for patients with\nmetastatic CRPC, there are many new questions arising regarding the optimal sequencing\nof these treatments as well as potential combinations of and old drugs.
Language: English
Subfield: Cancer Research
Open Access status: green
Funder: Sanofi
OpenAlex ID: W1603395292
Cites: 218
Cited by:
Related to: 9